21 employees
Lysogene is a pioneer in the basic research and clinical development of gene therapy for neurodegenerative disorders.
2009
$22M
from 3 investors over 3 rounds
LYSOGENE raised $3.4M on December 24, 2021
Investors: European Investment Bank
LYSOGENE raised $22M on May 21, 2014
Investors: Sofinnova Ventures, Russia technology fund and Novo Holdings